Results 11 to 20 of about 10,516 (266)

The Effect of Prolactinoma on Tear Film Function

Türk Oftalmoloji Dergisi, 2022
Objectives:To compare dry eye parameters in prolactinoma patients and healthy controls and evaluate their correlation with prolactin (PRL) levels and the duration of hyperprolactinemia.Materials and Methods:Consecutive patients with prolactinoma and ...
Cezmi Doğan, Ümit Yaşar Güleser, Oğuzhan Kılıçarslan, Burak Mergen, Özer Açbay, Güzin İskeleli   +5 more
doaj   +2 more sources

Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia

Iatreia, 2016
Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto, Gaviria-Maya, Juan Esteban, Henao-Flórez, Rodrigo Eduardo, Piedrahíta-Gutiérrez, Dany Leandro   +3 more
doaj   +2 more sources

Exploring retinal vessel density alterations in prolactinoma patients: Insights from OCTA imaging

Indian Journal of Ophthalmology
Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA). Design: A retrospective study.
Serife Ciloglu Hayat, Yusuf Cem Yilmaz, Merve Kelebek, Esra Hatipoglu   +3 more
doaj   +2 more sources

Wogonin inhibits the proliferation of prolactinoma through the PI3K/AKT signaling pathway [PDF]

Frontiers in Pharmacology
ObjectivesThis investigation sought to explore the inhibitory impact of wogonin on prolactinoma and elucidate its underlying mechanisms through network pharmacology, molecular docking (MD), and molecular biology experiments.MethodsTarget identification ...
Zhiyong Du, Zhiyong Du, Zhiyong Du, Zhiyong Du, Cuiping Sun, Cuiping Sun, Cuiping Sun, Cuiping Sun, Jiawei Wu, Jiawei Wu, Hongwei Gao, Hongwei Gao, Hongwei Gao, Hongwei Gao, Jialong Wu, Jialong Wu, Jialong Wu, Jialong Wu, You Zhou, You Zhou, You Zhou, You Zhou, Xuechao Wu, Xuechao Wu, Liping Shen, Liping Shen, Qing Wang, Qing Wang, Qing Wang, Qing Wang   +29 more
doaj   +2 more sources

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

Trials, 2021
Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen, Amir H. Zamanipoor Najafabadi, Iris C. M. Pelsma, M. Elske van den Akker-van Marle, Peter H. L. T. Bisschop, H. D. Jeroen Boogaarts, Arianne C. van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M. Dekkers, Madeleine L. Drent, Richard A. Feelders, Johan P. de Graaf, J. Hoogmoed, Kitty K. Kapiteijn, Melanie M. van der Klauw, Willy-Anne C. M. Nieuwlaat, Alberto M. Pereira, Aline M. E. Stades, Annenienke C. van de Ven, Iris M. M. J. Wakelkamp, Wouter R. van Furth, Nienke R. Biermasz, on behalf of the Dutch Prolactinoma Study Group   +23 more
doaj   +2 more sources

Prevalence of Autoimmune Thyroiditis and Other Autoimmune Diseases in Relation to Serum BAFF/APRIL Levels in Prolactinoma Patients [PDF]

Gazi Medical Journal
Objective: There may be an association between hyperprolactinemia and autoimmune diseases, possibly because of the immunostimulatory effect of prolactin.
Özlem Kanburoğlu Meletli, Alev Altınova, Başak Bolayır, Resul Karakuş, Meriç Coşkun, Mehmet Muhittin Yalçın, Müjde Aktürk, İlhan Yetkin, Füsun Saadet Toruner   +8 more
doaj   +2 more sources

Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole

Endocrinology, Diabetes & Metabolism Case Reports, 2016
In this report, we describe a female patient with both prolactinoma and psychotic disorder who was successfully treated with aripiprazole, a partial dopamine 2 receptor agonist.
Ilse C A Bakker, Chris D Schubart, Pierre M J Zelissen   +2 more
doaj   +2 more sources

Prolactinomas [PDF]

JAMA, 2021
Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including ...
Pauline P, Huynh, Lisa E, Ishii, Masaru, Ishii   +2 more
openaire   +4 more sources

Subtle Cognitive Impairments and Psychological Complaints in Patients With Prolactinoma Despite Biochemical Control. [PDF]

J Clin Endocrinol Metab
van Trigt VR, Andela CD, Bakker LEH, Brama SCM, Schmidt LE, Sneekes FM, Zeelenberg MW, Huisman SD, Bauduin SEEC, Dekkers OM, Verstegen MJT, van Furth WR, Pelsma ICM, Biermasz NR.   +13 more
europepmc   +2 more sources

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

Indian Journal of Endocrinology and Metabolism, 2017
Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare, Anurag R Lila, Rishikesh Patil, Milind Phadke, Prafulla Kerkar, Tushar Bandgar, Nalini S Shah   +6 more
doaj   +2 more sources